Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function
Conditions
Interventions
Rucaparib camsylate
Locations
6
Poland
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, Poland
Med Polonia Sp. z o.o.
Poznan, Poland
Zachodniopomorskie Centrum Onkologii w Szczecinie
Szczecin, Poland
BioVirtus Centrum Medyczne
Warsaw, Poland
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Northern Centre for Cancer Care
Newcastle upon Tyne, United Kingdom
Start Date
February 27, 2018
Primary Completion Date
September 27, 2019
Completion Date
February 24, 2021
Last Updated
June 9, 2023
NCT07213804
NCT07169851
NCT07159659
NCT00026884
NCT07481851
NCT06662786
Lead Sponsor
pharmaand GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions